Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701622 · ClinicalTrials.gov registry record · NA
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
A NA study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01701622 is a NA study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT01701622, a NA study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Hyperuricemia (high uric acid level) has been correlated to hypertension (high blood pressure) and overall cardiovascular disease risk in several studies. The relationship has even been noted to be independent of metabolic syndrome and kidney function. It has been repeatedly noted that hyperuricemia was an independent risk factor of death in those at high cardiovascular disease risk. A recent review concluded that there is strong evidence that hyperuricemia and gout are coupled with atherosclerosis and cardiovascular events. Although this correlation of hypertension and hyperuricemia is known, there has only been one published study that has evaluated if lowering the uric acid would reduce the blood pressure. The authors concluded that in newly diagnosed hypertensive adolescents, allopurinol decreased the blood pressure. Despite this, further evaluation of this therapeutic approach has not been studied. The hypothesis of this study is that febuxostat, a new xanthine oxidase inhibitor, has blood pressure lowering effects superior to allopurinol in patients diagnosed with gout.
Interventions
- DRUG febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01701622
The ClinicalTrials.gov registry entry for NCT01701622 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which febuxostat is the first listed.
NCT01701622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01701622 about?
NCT01701622 is a clinical study titled "The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study". Hyperuricemia (high uric acid level) has been correlated to hypertension (high blood pressure) and overall cardiovascular disease risk in several studies. The relationship has even been noted to be independent of metabolic syndrome and kidney function. It has been repeatedly noted that hyperuricemia...
What is the current status of trial NCT01701622?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2010-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01701622?
The interventions under investigation include: febuxostat (DRUG).
Who is sponsoring clinical trial NCT01701622?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.